Retatrutide 30mg
$200.00
Research-grade Retatrutide 30mg vial. Triple agonist activity across GLP-1 GIP and glucagon receptors.
Retatrutide 30mg — the highest-dose vial of LY3437943 for comprehensive research programmes. This vial provides sufficient compound for multi-arm dose-response studies or extended animal model experiments using Eli Lilly's triple GLP-1/GIP/glucagon receptor agonist. Phase II data showing 24.2% weight reduction at 48 weeks positions retatrutide as the most effective metabolic peptide compound currently in clinical development.
Molecular Data
Molecular Formula: C187H291N45O57 | Molecular Weight: 4130.6 g/mol | CAS Number: 2381606-29-3
Triple Receptor Mechanism
Acts simultaneously on GLP-1, GIP (at 8.9× endogenous potency), and glucagon receptors. The triple mechanism produces synergistic effects on appetite suppression, insulin sensitivity, and energy expenditure through three independent pathways — superior to single or dual agonist approaches.
Clinical Evidence
Phase II obesity trial: 17.5% mean weight loss at 24 weeks, 24.2% at 48 weeks at 12mg weekly dosing. Significant secondary improvements in lipid profiles, glycaemic control, blood pressure, and hepatic steatosis. Phase III TRIUMPH trials ongoing.
High-Volume Research
The 30mg vial is suited to comprehensive research programmes requiring larger quantities, including full dose-response curves from low to high dose, parallel treatment arms, or multi-tissue pharmacodynamic studies.
Future Research
Phase III TRIUMPH trials ongoing. Research extends to type 2 diabetes, MASLD, cardiovascular risk, and renal disease models.
Product Usage
This product is intended as a research chemical only. This designation allows the use of research chemicals strictly for in vitro testing and laboratory experimentation only. All product information available on this website is for educational purposes only.
Bodily introduction of any kind into humans or animals is strictly forbidden by law. This product should only be handled by licensed, qualified professionals.
This product is not a drug, food, or cosmetic and may not be misbranded, misused or mislabelled as a drug, food or cosmetic.



Reviews
There are no reviews yet.